Telormedix is teaming up with the Swiss Tropical and Public Health Institute (Swiss TPH) for a pilot study that aims to evaluate the firm’s TMX-201 adjuvant as part of developmental immunization strategies against malaria and Buruli ulcer. The pilot studies, to be carried out by researchers at the Swiss TPH, will compare Telormedix’ TMX-201 adjuvant with conventional adjuvant in combination with either a Plasmodium falciparum antigen candidate or a Mycobacterium ulcerans antigen candidate.
Telormedix is focused on developing drugs that harness the innate immune system for the treatment of cancer and autoimmune diseases. The firm’s adjuvant pipeline includes TMX-201 and other second- generation TLR7 molecules.
Lead therapeutic candidate, TMX-101, started in Phase I/II clinical development in June for the treatment of localized bladder cancer. The drug comprises a known immunomodulatory molecule that Telormedix says has a favorable safety profile and a demonstrated clinical efficacy in oncological and viral diseases. The firm has taken advantage of existing regulatory data and clinical experience to speed TMX-101 through preclinical development and into human trials.
Telormedix’ second therapeutic candidate TMX-202 is a second-generation small molecule TLR7 molecule in preclinical development for the topical treatment of skin cancers, bladder cancers, and other indications. Discovered through a collaboration with the University of California San Diego, TMX-202 has already successfully completed a number of in vivo studies, the firm explains. Its third therapeutic program, designated TMX-30X, is focused on developing candidates for treating autoimmune diseases.